Skip to content
Investing

Sigma Lithium: An Investor Profile of the Brazilian Producer After Its Stop-Start Year

Sigma Lithium mines and processes lithium in Minas Gerais, Brazil. Its operation, latest numbers, debt and new bond, expansion plans, the legal and liquidity risks, and the dates to watch.

Ana Cabral-Gardner, Sigma Lithium's chief executive and co-chair at the time, speaks into a microphone at a Brazilian Senate economic affairs committee hearing on critical minerals in July 2025.
Photo: Geraldo Magela/Agência Senado / Wikimedia Commons, CC BY 4.0

Sigma Lithium produces lithium oxide concentrate, a raw material for battery chemicals, from a single operation in south-east Brazil. After a year of court cases and stoppages, it is restarting production, refinancing its debt and planning to roughly double capacity. Here is what the company owns, what its latest numbers show and what comes next.

What Sigma does and where

Sigma's operation, Grota do Cirilo, lies in the municipalities of Araçuaí and Itinga in the Jequitinhonha Valley of Minas Gerais. The company owns it outright through its Brazilian subsidiary, Sigma Mineração. It holds 29 mineral rights covering 185 square kilometres within a land package of about 19,000 hectares.

Production began in April 2023. The company calls its processing facility the Cleantech Industrial Plant. Alongside its cost at the plant gate, it reports a cost per tonne including freight and insurance (CIF). Its licences also cover a second mine, Barreiro, and a second processing plant.

Sigma is listed on Nasdaq and the TSX Venture Exchange under the symbol SGML, and on the ASX as SAU through depositary interests. Ana Cabral is co-chairperson and chief executive. The company had 112,690,313 shares in issue at 30 September 2026 and reports in US dollars.

Sigma Lithium: share price, chart and news

Key numbers

MeasureQ3 2026Nine months 2026
Production7,300t66,300t
Gross revenue$22.3m$115.4m
Adjusted EBITDAminus $6.7m$35.7m
Net loss$25.9m$17.4m
Operating cash flow$24.2m$51.3m
CIF cost per tonne$518$505

The third quarter was hit by two suspensions. The first ran from 17 July to 22 August, until Sigma entered a conduct adjustment agreement with Minas Gerais authorities. The second began on 30 September, when a federal court issued a preliminary injunction in a lawsuit brought by a non-governmental organisation. A federal appeals court upheld Sigma's environmental licences on 6 October, and production restarted in early October. By 10 November the company had produced 11,000 tonnes of high-grade concentrate since the restart.

Realised prices averaged $1,485 a tonne in the quarter. Sigma's all-in sustaining cost guidance for 2026 is $668 a tonne, cut from $710 in a 2 November preview; the third quarter came in at $642.

Balance sheet and the new bond

At 30 September Sigma held $10.4m of cash and owed $140.1m in loans and export prepayments, $127.0m of it due within a year. Net debt was $105m on the company's measure. Working capital was negative by $218.6m, and the accounts say this may cast doubt on its ability to continue as a going concern, although management is comfortable preparing them on that basis.

The $125m convertible bond priced on 2 November is meant to change that profile. It pays a fixed 7%, matures in about November 2031, lets holders demand repayment after about three years and converts at $6.51 a share. The money repays the Synergy Capital export prepayment, which cost about 11.45%. Sigma says pro forma short-term debt falls to about $19m, while pro forma net debt is $145m.

If all the bonds converted, about 19.2m new shares would be issued, roughly 17% of the current share count on our calculation. Sigma says it has not issued equity since 2021. It also says it has been self-funded since July 2023 and has repaid more than $90m of debt since the second quarter of 2024.

Beyond the bond, the company pointed in its third-quarter preview to up to $62m of potential short-term liquidity: about $10m of receivables for high-grade sales, about $20m of unsold low-grade inventory and $32m of remaining offtake instalments. Sigma said the timing of that money depends on sales and on lithium prices, so it is not cash in hand.

Growth plans

  • 2027: 330,000 tonnes from the first plant, made up of about 68,000 tonnes a quarter of high-grade concentrate and 15,000 tonnes a quarter from tailings reprocessing, at an all-in sustaining cost of $620 a tonne.
  • Phase 2: construction of a second plant resumes in 2027, adding 250,000 tonnes a year to reach 580,000, funded by a BRL 492m loan from development bank BNDES with a 16-year term.
  • Phase 3: targeted for 2028, taking capacity to 830,000 tonnes a year, supplied by a second mine with about 30 million tonnes of resources.

Sigma estimates that at concentrate prices of $1,000 to $1,500 a tonne, the first plant would generate $125m to $290m of pre-tax cash flow in 2027. These are company projections that depend on prices and on operations running without interruption, which was not the case in 2026.

Risks and what to watch

Main risks

  • Permits and courts: further court steps follow the October appeal ruling, including a court-appointed expert's assessment, and mining regulator ANM has issued an improvement notice on a slope at the depleted North Pit, which Sigma says is not a stoppage
  • Liquidity: thin cash and negative working capital, with going-concern wording in the accounts
  • Controls: auditor Grant Thornton gave an adverse opinion on internal control over financial reporting at the end of 2025; Sigma targets remediation by the end of 2026
  • Disputes: $27.8m of supplier balances disputed by Sigma at 30 September, plus claims it rates as possible losses; an arbitration brought by LG Energy Solution was decided in Sigma's favour
  • Prices: revenue depends on volatile lithium concentrate prices
  • Dilution: the convertible bond could add about 19.2m shares
TimingEvent
On or about 16 Nov 2026Closing of the $125m convertible bond and repayment of Synergy Capital
Q4 2026Sale of about 21,000 tonnes of high-grade-equivalent inventory
End of 2026Target for fixing internal control weaknesses
2027Phase 2 construction restarts; 330,000 tonne production goal
2028Phase 3 target of 830,000 tonnes a year
About Nov 2029Bondholders' option to demand repayment

For investors, the central question is whether Sigma can run its plant without further legal or regulatory stoppages long enough to rebuild cash, because every expansion plan and cash-flow projection assumes it can.

Sources

Related stories

Markets

Sigma Lithium Swings to a $25.9m Quarterly Loss as Brazil Suspensions Cut Output

Two stoppages in Brazil cut Sigma Lithium's third-quarter output to about 7,300 tonnes and left a $25.9m loss. Production has restarted and a $125m bond refinances its costliest…

Investing

Anson Resources Profile: A Permitted Utah Lithium Project With A$3.5m in the Bank

Anson Resources has the main permits for its Green River lithium brine project in Utah and US$406.5m of state incentives, but held only A$3.5m of cash against a build cost of about…

Investing

Frontier Lithium: Investor Profile of the Ontario Developer Behind the PAK Lithium Project

Frontier Lithium is developing the PAK lithium project in northwestern Ontario with Mitsubishi. This profile covers its study numbers, cash, share count, main risks and permitting…

Investing

Ero Copper: Investor Profile of the Brazil-Focused Copper and Gold Producer

Ero Copper mines copper at Caraíba and Tucumã and gold at Xavantina, all in Brazil. Its assets, record Q3 2026 numbers, debt, share count, main risks and the milestones to watch.

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…